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Abstract 
Non-safety critical software developers have been reaping the benefits of adopting agile practices for a 
number of years. However, developers of safety critical software often have concerns about adopting 
Agile practices. Through a literature review this research identified the perceived barriers to following 
agile practices when developing medical device software. A questionnaire based survey was also 
conducted with medical device software developers in Ireland to determine what the actual barriers 
are to adopting agile practices. In addition a comparison is performed between the perceived and ac-
tual barriers and the results are reported. 
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1   Introduction 
The popularity of agile practices is on the rise [1]. Agile practices appear to offer a “silver bullet” [2] for 
all of the problems associated with traditional plan driven software development lifecycles. A number 
of surveys have been completed which reinforce this believe [3, 4]. However, a large amount of re-
search has been conducted into the success of adopting agile practices which is broad and does not 
expressly focus on specific domains within the software development industry i.e. safety critical soft-
ware development.  
Non-safety critical software is developed in accordance with a customer’s requirements, but safety 
critical software must be developed in accordance with both a customer’s requirements and national 
and/or international regulatory constraints.  These regulatory constraints are dictated by the region in 
which it is planned to market the software, be it standalone or part of a hardware device.   For exam-
ple,  if a medical device is to be marketed  in the United States (US) it must be developed in accord-
ance with the Food and Drug Administration (FDA) quality regulations, guidance documents and ap-
proved standards [5, 6].  Software developed for use within safety critical domains is typically devel-
oped in accordance with the Waterfall Model or V-Model software development lifecycles [6, 7]. These 
lifecycles are defined by upfront design with high importance placed upon the production of documen-
tation [6]. These models produce the necessary deliverables required to achieve regulatory conform-
ance.  
Our research is focused on the development of software for use within the medical device domain. 
Regulatory requirements and development standards such as [8, 9] do not dictate the use of a particu-
lar lifecycle when developing  medical device software. In fact they state that medical device software 
can be developed using a traditional, iterative and/or evolutionary approach. Despite this, medical 
device software developers typically develop software in accordance with the V-Model [7]. Whilst the 
V-Model produces necessary deliverables such as traceability between requirements and all stages of 
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the software development lifecycle [10] it is seen as being rigid and inflexible in the event of a change 
once development has begun [11].  
This research was initiated by performing a literature review. One of the objectives of undertaking 
this literature review was the identification of the perceived barriers to adopting Agile practices when 
developing medical device software. Also as part of this research a questionnaire based survey was 
conducted amongst medical device software developers in Ireland. The aim of this survey was to 
evaluate the findings of the literature review and to learn what are the actual barriers to adopting agile 
practices when developing medical device software.  
The remainder of this paper is structured as follows: Section 2 provides information as to our on-
going research in this area and how this aspect of our work fits into this research. Section 3 details the 
perceived barriers to selecting and implementing agile practices when developing medical device 
software based on the results from our literature review. Section 4 outlines the approach taken by 
questionnaire based survey conducted amongst medical device manufacturers in Ireland. Section 5 
provides the results of the survey and within section 6 a comparison is performed between the per-
ceived barriers and the actual barriers to adopting Agile practices. 
2   Research Objectives 
As part of this on-going research the following research questions has been identified. This research 
is: 
 
1. What are the issues associated with developing medical device software? 
2. What are the issues with developing medical device software using a traditional software de-
velopment lifecycle? 
3. Which agile practices are suited to developing medical device software? 
4. To what extent do existing medical device software development lifecycles need to be tailored 
to incorporate suitable agile practices? 
 
The results from the research outlined in this paper will be used to help address the third research 
question. By identifying actual barriers to the adoption of agile practices specific practices can be dis-
counted and the remaining agile practices can be evaluated for suitability. These research questions 
were formed following the completion of a literature review. This literature review began by broadly 
looking at generic software development lifecycles. The focus of the literature review moved to the 
development of safety critical software and then onto the development of software in the medical de-
vice industry. Following this phase of the literature review, research was conducted into agile software 
development. This involved examining   mainstream methodologies such as Scrum and XP. Once this 
was completed we then focused upon the adoption of agile practices in the development of safety 
critical software.  Finally, we considered the adoption of agile practices in the development of medical 
device software. This literature revealed a number of perceived barriers to adopting agile practices 
when developing medical device software.  
Following the literature review a questionnaire based survey was conducted amongst medical de-
vice software developers in Ireland. The objective of this survey was to evaluate the findings of the 
literature review and to learn what the actual barriers to adopting agile practices are. 
3   Perceived Barriers to Agile Adoption 
As discussed in section 1, software developed for use in or as a medical device must meet the regula-
tory requirements of the region where the device is being marketed. As a result many of the perceived 
barriers to adopting agile practices in developing medical device software are associated with regula-
tory controls [12]. The focus of this research is the identification of the perceived barriers that have a 
direct impact on the development process of medical device software and the implementation of agile 
methods in this context. Additional barriers do exist, but a number of these are organisational barriers 
that do not have a direct impact on the development of medical device software. An example of such 
an organisational barrier is that Human Resource policies and processes do not cater for the require-
ments of an Agile team [13]. The literature review performed identified the following perceived barriers 
to the adoption of agile practices when developing medical device software. 
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The FDA General Principles of Software Validation (GPSV) [9] require manufacturers to explicitly 
document requirements prior to implementation and test procedures [14]. This would appear to be an 
apparent barrier to adopting agile practices as one of the fundamental principles of the agile Manifesto 
[15] is “working software over comprehensive documentation”. Combined with this another central 
principle of agile software development is that requirements are fluid and changes in requirements can 
be easily accommodated and are even welcomed throughout a development project [16]. Without fully 
refining requirements prior to the beginning of a project the process of traceability can be difficult and 
traceability between requirements and all stages of development is required by the FDA [17].   
As safety critical software such as medical device software can place patients, clinicians and third 
parties at potential risk, medical device software developers must perform adequate risk management 
activities to ensure the software they are developing is safe and reliable. Boehm and Turner [13] sug-
gest that risk management activities can be a barrier to adopting agile practices as agile practices do 
not provide sufficient guidance as how to perform the necessary risk management activities.  
Another perceived barrier to adopting agile practices is that software developed using agile practic-
es is of a lower quality than software developed following traditional plan driven lifecycles [13]. As 
medical device software is safety critical it must be developed to the highest quality possible. 
Agile methodologies such as XP recommend short releases with continuous feedback [18]. When 
developing medical device software it is not possible to release incomplete software and await feed-
back as the software must be fully tested and working before it is used in patient treatment [19].  
An additional potential barrier to adopting agile practices in the development of both safety critical 
and non-safety critical software is the loss of management control. Agile methodologies recommend 
that development teams are self-organising. This process of self-organising teams removes some of 
the decision making powers from management [20]. This can result in a loss of management control 
and for agile practices to succeed organisational support is required [21].  
4   Survey of Medical Device Software Developers in Ireland  
In order to gain an understanding as to what the perceived barriers and actual barriers are to the 
adoption of agile practices we performed a questionnaire based survey with medical device software 
development organisations within Ireland. The literature review outlined in section 1 identified the per-
ceived barriers to agile adoption and the survey results have been used to identify actual barriers to 
adopting agile practices when developing medical device software. 
Within Ireland there are approximately 160 medical device manufacturers [22]. No research has 
been conducted to date to suggest how many of these organisations develop medical device software. 
As a result when determining sufficient sample size a decision was made to assume all of these or-
ganisation develop medical device software. Using sample size equations a sufficient sample size was 
determined as twenty organisations. 
 As a result of this the survey was conducted amongst twenty medical device software develop-
ment organisations in Ireland with multiple responses from each organisation. These organisations 
ranged from small indigenous manufacturers to large multinational manufacturers. The devices pro-
duced by theses manufacturers range from Class I – Low Risk to Class III – High Risk1 products. The 
primary goal of this survey was to gain a deeper insight into the medical device software development 
industry to further assist with our on-going research. Participants who took part in the survey included 
all levels of the development team and internal stakeholders such as managers and senior manage-
ment.  
The survey was developed in accordance with “Introduction to Research Methods: A Practical 
Guide for Anyone Undertaking a Research Project” and “Designing Social Research”  [23, 24]. These 
books outline effective methods for constructing and undertaking a questionnaire based survey with 
the objective of achieving the maximum amount of relevant information. The survey began by asking 
participants what was their role in the organisation and how long they have been working in the medi-
cal device industry. The responses from these questions were used to qualify the expertise of the par-
ticipants and to support the validity of their responses.   In addition the fact that we received more than 
one response from each company enabled us to validate the quality of these responses from each 
company.  
                                                     
1 This safety classification is defined by the European Council Medical Device Directive 93/42/EEC. 
Class I devices are deemed to pose low risk to patients, users and third parties and Class III devices 
are deemed to pose potentially life threatening risk to patients, users and third parties. 
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The first piece of significantly relevant information obtained by the survey was which software de-
velopment lifecycle the organisations are following. As part of this on-going research, recommenda-
tions will be made as to how adopting agile practices can resolve problems associated with the current 
lifecycle being followed.  
Following on from this question, participants were provided with a list of activities that are required 
to be completed in the development of safety critical software. Participants were requested to rate how 
much importance they place on each of these activities and to rate how effective they deem their or-
ganisation to be at performing these activities. The objective of this question was to understand which 
areas of safety critical software development are being performed most effectively. Again as part of 
this on-going research, information is being collected that will identify which stages of development 
pose the most difficulty to medical device software developers. This information will eventually be 
used to help answer research questions 1 and 2.  
Finally participants were asked a series of questions relating to agile software development. Partic-
ipants were provided with a list of potential agile barriers and asked to select which barriers they per-
ceived would prevent the adoption of agile practices. The goal of this question was to evaluate the 
findings of the literature review. Participants where then asked what the actual barriers were within 
their own organisation to the adoption of agile methods. This question was used to establish what 
these barriers are and if commonality could be identified across organisations as to what actual barri-
ers exist in relation to agile adoption. A barrier being defined as an actual barrier does not imply that 
the barrier is insurmountable. To maximise the amount of relevant information gathered, space was 
provided for the respondents to add additional information and/or comments for each question as they 
deemed necessary. 
5   Results of Survey 
As discussed, one of the objectives of the survey was to establish the actual barriers faced by medical 
device software developers. The results of the survey have also been used to evaluate the findings of 
the literature review in this context. 
The following results are preliminary as this research is still on-going. The survey revealed that 
100% of the respondents who are currently marketing medical device software are developing it for 
use in Europe. In addition, 79% of these are also developing medical device software for use in the 
US. 
The survey identified that 50% of the organisations are developing software in accordance with the 
V-Model.  An important finding was that another 25% of the organisations are developing medical 
device software in accordance with agile practices. The remaining 25% of organizations are develop-
ing software in accordance with other development lifecycles such as the Waterfall model.  
As part of the survey, respondents were asked what they believe to be the perceived barriers to ag-
ile adoption. The survey revealed that 25% of respondents reported “Lack of Documentation” as a 
barrier to agile adoption.  In addition 25% of respondents reported “Regulatory Compliance”, whilst 
16% of respondents reported “Lack of Up-Front planning” and 17% of respondents reported “Insuffi-
cient coverage of risk management activities” as barriers to agile adoption. These results were con-
sistent with the findings from the literature review. 
Finally, respondents of the survey were asked what the actual barriers to adopting agile practices 
are.  Of the respondents 50% reported “Lack of Experience”, 33% reported that having to change the 
existing lifecycle as a barrier to agile adoption, 16% reported “Management Opposed to Change “and 
16% reported team size as a barrier to agile adoption. A further 17% reported that getting stakeholder 
buy in as a barrier and 17% reported the level of retraining required as another barrier to agile adop-
tion.  
6   Comparison between Perceived and Actual Barriers 
Table 1 presents a list of the perceived barriers based on our literature review and the actual barriers 
to agile adoption when developing medical device software based on our survey results.  
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Table 1 Perceived and Actual Barriers to Agile adoption 
Perceived Barriers Actual Barriers 
• Regulatory Control • Regulatory Control 
• In-sufficient coverage of Risk Man-
agement Activities 
• Requirements Management 
• In-sufficient coverage of Risk Man-
agement Activities 
• Lack of  up-front planning 
• Traceability issues • Lack of documentation 
• Loss of management control • Management opposed to change 
• Lower quality software • Team size 
 • Modification of existing lifecycle 
 • Lack of Experience using agile 
• Getting Stakeholder Buy In 
• Level of Retraining Required 
 
It can be seen in table 1 that a number of the perceived barriers are also actual barriers to using agile 
practices when developing medical device software. An important point to emerge from our research 
is how requirements can be identified and successfully managed in the context of utilising agile prac-
tises. Regulatory bodies require medical device software developers to document requirements prior 
to development. These requirements are then used during the development stages to provide tracea-
bility. Agile principles dictate that requirements be fluid throughout a development project and this can 
be seen as a barrier as we have outlined in section 3.  
  However, regulatory bodies do recognise the acceptability of what can be termed an agile 
approach to requirements. The FDA GPSV states [9]:  
 
“Most software development models will be iterative. This is likely to result in several versions of 
both the software requirement specification and the software design specification. All approved 
versions should be archived and controlled in accordance with established configuration man-
agement procedures”.  
 
This emerged from our detailed analysis of the relevant regulations, standards and guidance docu-
ments. This was not evident from the published academic literature in this area, in fact the opposite 
was the case as we have stated.  
This provides an example of how the perceived barriers to agile adoption can be overcome. Further 
research will be undertaken to evaluate and determine how each of the other barriers identified can be 
addressed by employing specific agile practices or by integrating agile practices with a plan driven 
lifecycle. 
7   Conclusions  
A number of barriers to adopting agile practices when developing medical device software have been 
identified through a literature review and questionnaire based survey. Medical device software devel-
opers must develop software in accordance with regulatory requirements and as a result a number of 
the barriers to agile adoption are associated with the process of achieving regulatory conformance. 
Regulatory bodies and medical device software development standards do not dictate the usage of 
a specific software development lifecycle for developing medical device software [8, 9] . Regulatory 
bodies have a set of deliverables which device manufacturers must deliver. Medical device software 
developers can develop software in accordance with agile practices once they provide the necessary 
deliverables. Research conducted by Rasmussen et al and Rottier et al [25, 26], identified that no 
single agile methodology could be strictly adhered to when developing medical device software as no 
single agile methodology provides sufficient coverage of all of the areas necessary to achieve regula-
tory conformance. However, Rasmussen et al and Rottier et al [25, 26]  did identify that selectively 
choosing appropriate agile practices and integrating them with a plan driven lifecycle can reap the 
benefits of employing agile practices whilst still producing the necessary regulatory deliverables. This 
is an area we plan to investigate further as part of our on-going research. 
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